tradingkey.logo
tradingkey.logo
Search

Vaxcyte Inc

PCVX
Add to Watchlist
54.080USD
-1.880-3.36%
Close 07-31 16:00ETQuotes delayed by 15 min
7.81BMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey Chart
Intraday
1m
30m
1h
D
W
M
D

Today

-3.36%

5 Days

-1.06%

1 Month

-6.97%

6 Months

+0.95%

Year to Date

+17.21%

1 Year

+59.29%

Key Figures
56.100Open
56.387High
793.22KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.55%Turnover Ratio
55.960Prev. Close
53.530Low
36.71MTurnover
LossP/E Static
2.60P/B
0.00%Div Yield TTM
-28.14%ROA
65.00052wk High
0.74Volume Ratio
-463.93MNet Profit
144.31MShares
-6.8945EPS TTM
1.26Beta
-30.55%ROE
29.08052wk Low
5.11%Amplitude
--Gross Margin
7.81BMarket Cap
-1.51Reward/Risk
2.76%Risk Rate

Vaxcyte Inc News

More news coming soon, stay tuned...

Earnings Forecast

Analyst Rating

Based on 11 analysts
Buy
Current Rating
109.000
Target Price
+105.74%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Vaxcyte Inc
PCVX
11
Beigene Ltd
ONC
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
Ionis Pharmaceuticals Inc
IONS
25
Insmed Inc
INSM
23
1
2
3
...
99

Indicators

Indicators
Sell(2)
Neutral(5)
Buy(0)
Indicators
Value
Direction
MACD(12,26,9)
-0.953
Neutral
RSI(14)
46.924
Neutral
STOCH(KDJ)(9,3,3)
30.788
Neutral
ATR(14)
2.377
High Vlolatility
CCI(14)
-85.993
Neutral
Williams %R
73.693
Sell
TRIX(12,20)
0.060
Sell
StochRSI(14)
44.123
Neutral
Moving Average
Sell(4)
Neutral(0)
Buy(2)
Indicators
Value
Direction
MA5
54.624
Sell
MA10
55.296
Sell
MA20
56.478
Sell
MA50
52.944
Buy
MA100
54.996
Sell
MA200
52.057
Buy

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Vaxcyte Inc Info

Vaxcyte Inc. is a clinical-stage vaccine innovation company. The Company is engaged in developing spectrum conjugate and protein vaccines to prevent or treat bacterial infectious diseases. Its pipeline includes VAX-31, a 31-valent PCV candidate advancing to a Phase III adult clinical program and being evaluated in a Phase II infant clinical program, which is being developed for the prevention of invasive pneumococcal disease (IPD) in adults and infants and is the broadest-spectrum pneumococcal conjugate vaccine (PCV) candidate in the clinic. VAX-24, the Company’s 24-valent PCV candidate, is designed to cover more serotypes than any infant PCV on-market and is being evaluated in a Phase II infant study. Its pipeline also includes VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections; VAX-PG, a therapeutic vaccine candidate designed to slow or stop the progression of periodontal disease; and VAX-GI, a vaccine candidate designed to prevent Shigella.
Ticker SymbolPCVX
CompanyVaxcyte Inc
CEOPickering (Grant E)
Websitehttps://vaxcyte.com/

Shareholders

Shareholders
Shareholders
Proportion
Janus Henderson Investors
9.27%
Fidelity Management & Research Company LLC
7.98%
T. Rowe Price Investment Management, Inc.
7.82%
RA Capital Management, LP
7.43%
BlackRock Institutional Trust Company, N.A.
6.02%
Other
61.48%

FAQs

What is the current price of Vaxcyte Inc (PCVX)?

The current price of Vaxcyte Inc (PCVX) is 54.08.

What is the symbol of Vaxcyte Inc?

The ticker symbol of Vaxcyte Inc is PCVX.

What is the 52-week high of Vaxcyte Inc?

The 52-week high of Vaxcyte Inc is 65.00.

What is the 52-week low of Vaxcyte Inc?

The 52-week low of Vaxcyte Inc is 29.08.

What is the market capitalization of Vaxcyte Inc?

The market capitalization of Vaxcyte Inc is 7.80B.

Is Vaxcyte Inc (PCVX) currently rated as Buy, Hold, or Sell?

According to analysts, Vaxcyte Inc (PCVX) has an overall rating of Buy, with a price target of 109.00.

What is the Earnings Per Share (EPS TTM) of Vaxcyte Inc (PCVX)?

The Earnings Per Share (EPS TTM) of Vaxcyte Inc (PCVX) is -5.63.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.